Loading...
MTAA
PHN
Market cap496mUSD
Apr 07, Last price  
47.15EUR
1D
-2.28%
1Q
-11.04%
IPO
240.43%
Name

Pharmanutra SpA

Chart & Performance

D1W1MN
P/E
35.43
P/S
4.50
EPS
1.33
Div Yield, %
1.80%
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
16.70%
Revenues
101m
+21.15%
26,254,66432,998,46937,784,56446,672,50353,811,00058,480,00068,578,00083,394,000101,034,000
Net income
13m
-14.73%
2,571,9333,850,8386,030,4898,557,4978,454,00014,072,00013,771,00015,048,00012,832,000
CFO
12m
-16.41%
05,861,3865,706,2876,436,10011,983,00011,791,00020,413,00014,466,00012,092,000
Dividend
May 06, 20240.85 EUR/sh

Profile

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.
URL
https://www.pharmanutra.it/
IPO date
Jul 18, 2017
Employees
Domiciled in
IT
Incorporated in
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
101,034
21.15%
83,394
21.60%
Cost of revenue
75,803
84,899
Unusual Expense (Income)
NOPBT
25,231
(1,505)
NOPBT Margin
24.97%
Operating Taxes
10,428
8,370
Tax Rate
41.33%
NOPAT
14,803
(9,875)
Net income
12,832
-14.73%
15,048
9.27%
Dividends
(7,714)
(6,852)
Dividend yield
1.41%
1.14%
Proceeds from repurchase of equity
(1,651)
(2,331)
BB yield
0.30%
0.39%
Debt
Debt current
4,585
3,616
Long-term debt
25,042
14,859
Deferred revenue
Other long-term liabilities
6,958
9,307
Net debt
4,297
(3,580)
Cash flow
Cash from operating activities
12,092
14,466
CAPEX
(13,249)
(23,157)
Cash from investing activities
(14,702)
(23,715)
Cash from financing activities
(516)
1,891
FCF
2,519
(22,742)
Balance
Cash
25,118
26,861
Long term investments
212
(4,806)
Excess cash
20,278
17,885
Stockholders' equity
54,407
68,358
Invested Capital
69,102
58,572
ROIC
23.19%
ROCE
28.23%
EV
Common stock shares outstanding
9,668
9,672
Price
56.40
-9.47%
62.30
-17.37%
Market cap
545,255
-9.51%
602,573
-17.45%
EV
549,552
598,993
EBITDA
27,648
(361)
EV/EBITDA
19.88
Interest
802
60
Interest/NOPBT
3.18%